We are an innovative biotech company developing a proprietary new class of antibiotics that are active against drug-resistant bacteria.
Our first product will improve the quality of life for 80-100 million atopic dermatitis patients worldwide. We develop it up to and including phase II clinical studies before licensing to a partner. The program management and business development are internal, all the other activities are outsourced. We are in pre-clinical development (financed), and are looking for financing for the clinical development which is anticipated to commence H2-2014.